Home / Health / New Heart Failure Drug Shows Promise
New Heart Failure Drug Shows Promise
19 Nov
Summary
- Winrevair trial demonstrated significant reduction in pulmonary vascular resistance.
- The Cadence trial assessed the drug in patients with CpcPH due to HFpEF.
- No approved therapies currently exist for CpcPH due to HFpEF.
The Phase II Cadence trial for MSD's investigational drug, Winrevair (sotatercept-csrk), has achieved its primary goal. The trial focused on patients experiencing combined post- and precapillary pulmonary hypertension (CpcPH) stemming from heart failure with preserved ejection fraction (HFpEF), a condition for which no treatments are currently approved. This positive outcome signifies a potential breakthrough in managing this complex cardiac issue.
The randomized, double-blind, placebo-controlled Cadence trial demonstrated a statistically significant reduction in pulmonary vascular resistance (PVR) over 24 weeks when compared to a placebo. The drug's safety profile in this study was consistent with previous observations, bolstering confidence in its therapeutic potential. The trial involved 164 patients with NYHA functional class II or III, assessing various metrics including invasive hemodynamics and exercise capacity.
MSD plans to advance Winrevair to Phase III trials, aiming to bring a novel therapy to patients suffering from CpcPH due to HFpEF. This development follows positive Phase III Hyperion trial results for Winrevair in pulmonary arterial hypertension (PAH), indicating broad potential for the drug in treating pulmonary vascular diseases.
